Latest Research Development News

Anatara Lifesciences has obtained a $400,000 loan advance from a major shareholder group against its estimated R&D tax refund for the first half of FY2025, providing crucial funding to support ongoing clinical trials and product development without immediate capital raising.

Truscott Mining Corporation’s March 2025 report reveals advancing structural geology insights and robust funding underpinning expanded exploration at Tennant Creek’s Westminster project.

Energy World Corporation has appointed a global investment bank to spearhead funding efforts for its LNG and power projects in the Philippines, while reporting a $3.62 million operating cash outflow and the resignation of a senior executive.

Terragen Holdings has launched its new probiotic products for ruminants, initiated multiple key trials including methane mitigation and crop yield studies, and secured a US patent allowance, positioning itself for global market expansion.

1414 Degrees Ltd advances its transformation into a full-service decarbonised energy provider, delivering key technology and commercial milestones in Q3 FY25 while maintaining a stable cash position.

Empire Energy Group reported significant cash outflows in Q1 2025 driven by exploration and infrastructure investments but bolstered its liquidity with new financing facilities, including a Midstream Infrastructure Facility for the Carpentaria Gas Plant.

CurveBeam AI Limited reported a $4.367 million net operating cash outflow for Q3 2025 but anticipates a significant improvement in cash flow driven by device installations and customer receipts, with no immediate plans for capital raising.

Universal Biosensors reported a 28% increase in customer receipts to $1.6 million for Q1 2025, alongside improved cash flow and plans for a new product launch later this year.

OncoSil Medical has reported a remarkable 233% increase in dose sales for Q3 FY25, alongside significant regulatory approvals and strategic expansions that position the company for accelerated growth.

ReNerve Limited reported a 39% sales increase in Q3 FY25 alongside compelling clinical validation of its NervAlign® Nerve Cuff and strategic international partnerships, positioning the company for broader market penetration.

Emyria Limited reports sustained clinical success in its PTSD program, launches a new treatment-resistant depression therapy, and opens a second Empax Centre to meet growing demand. The company is progressing funding discussions with health insurers and government bodies to support expansion.

Titomic Limited has entered a strategic teaming agreement with REPKON USA to jointly develop and apply its kinetic fusion cold spray technology for advanced defense manufacturing, focusing on repairs and performance enhancements of critical military assets.